{"doi":"10.5588/ijtld.24.0616","title":"Challenges to initiate and complete a 4-month rifapentine-moxifloxacin TB treatment regimen","abstract":"<sec><title>BACKGROUND</title>In February 2022, the U.S. Centers for Disease Control and Prevention (CDC) recommended a 4-month rifapentine-moxifloxacin based regimen (4-HPMZ) for treating drug-susceptible pulmonary TB. We describe 4-HPMZ implementation, treatment outcomes, and regimen tolerability at New York City (NYC) Health Department TB clinics.</sec><sec><title>METHODS</title>A multidisciplinary workgroup developed a 4-HPMZ implementation plan and protocol based on CDC patient eligibility guidance. Treatment outcomes were classified as 'completed' when 4-HPMZ was completed within 5 months or 'discontinued' when 4-HPMZ was stopped due to clinical or programmatic reasons. Adverse events (AEs) included abnormal lab results, or any medication-related concern reported by patients.</sec><sec><title>RESULTS</title>Between April 2022 to December 2023, 617 patients with TB visited NYC Health Department TB clinics; for 4-HPMZ, 333 (54%) were ineligible and 284 (46%) were eligible. Of the eligible patients, 40 (14%) were prescribed 4-HPMZ; of these, 36 initiated 4-HPMZ treatment, 13 (36%) completed treatment, and 23 (64%) discontinued. A total of 15 patients (42%) discontinued due to AEs.</sec><sec><title>CONCLUSION</title>Significant programmatic and clinical challenges were associated with initiation and completion of 4-HPMZ treatment. As a result, few patients completed treatment. Further assessment is needed to identify populations most likely to initiate and complete 4-HPMZ.</sec>.","journal":"The International Journal of Tuberculosis and Lung Disease","year":2025,"id":523726,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":4,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9672,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":867248,"name":"Grace Gao","orcid":"0000-0001-6109-7406","position":1,"is_corresponding":false},{"id":1150367,"name":"M. M. Salerno","orcid":null,"position":2,"is_corresponding":false},{"id":174341,"name":"MI Whitehead","orcid":null,"position":3,"is_corresponding":false},{"id":1397114,"name":"Dominique Juste","orcid":null,"position":4,"is_corresponding":false},{"id":1397115,"name":"C. C. Buchanan","orcid":null,"position":5,"is_corresponding":false},{"id":867247,"name":"Christine Chuck","orcid":"0000-0001-9359-8491","position":6,"is_corresponding":false},{"id":1397116,"name":"Faina Iskhakova","orcid":null,"position":7,"is_corresponding":false},{"id":867244,"name":"Michelle Macaraig","orcid":"0000-0002-2891-9903","position":8,"is_corresponding":false},{"id":1032458,"name":"Felicia Dworkin","orcid":"0000-0003-4344-8561","position":9,"is_corresponding":false},{"id":867241,"name":"Joseph Burzynski","orcid":"0000-0002-7109-7669","position":10,"is_corresponding":false},{"id":867249,"name":"Diana Nilsen","orcid":"0000-0001-7031-6615","position":11,"is_corresponding":false},{"id":1397113,"name":"Maria E. Galvis","orcid":null,"position":0,"is_corresponding":true}],"reference_count":0,"raw_metadata":null,"created_at":"2026-07-19T02:50:07.396155Z","pmid":"40579760","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}